pmid	doi	year	title	Hugo_Symbol
28840016	10.21037/jtd.2017.06.20	2022	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.	NF1
33730843	10.3324/haematol.2020.269431	2022	Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.	NF1
34308104	10.1093/jncics/pkab007	2022	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.	NF1
34339711	10.1016/j.brainres.2021.147594	2022	Role of the parental NF1 carrier in effects of pharmacological inhibition of anaplastic lymphoma kinase in Neurofibromatosis 1 mutant mice.	NF1
34995897	10.1016/j.cancergen.2021.12.005	2022	A complex KMT2A::AFF3 fusion resulting from a three-way chromosomal rearrangement in pediatric B lymphoblastic leukemia.	NF1
35077772	10.1016/j.bbr.2022.113767	2022	Long-term effects of pharmacological inhibition of anaplastic lymphoma kinase in neurofibromatosis 1 mutant mice.	NF1
35098592	10.1111/jdv.17974	2022	Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients.	NF1
35363510	10.1200/JCO.21.02840	2022	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.	NF1
35373885	10.1002/pbc.29575	2022	Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.	NF1
35515133	10.3389/fonc.2022.851572	2022	Case Report: Precision Medicine Target Revealed by <i>In Vitro</i> Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis.	NF1
35689207	10.1186/s12943-022-01583-z	2022	Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.	NF1
35749292	10.1148/rg.210235	2022	Neurofibromatosis from Head to Toe: What the Radiologist Needs to Know.	NF1
35777330	10.1016/j.anndiagpath.2022.151997	2022	VEGF and VEGFR family members are expressed by neoplastic cells of NF1-associated tumors and may play an oncogenic role in malignant peripheral nerve sheath tumor growth through an autocrine loop.	NF1
35870258	10.1016/j.lungcan.2022.07.011	2022	Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.	NF1
35920299	10.1096/fj.202200061RR	2022	Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context.	NF1
31439678	10.3324/haematol.2019.230375	2021	Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.	NF1
32366782	10.1097/MPH.0000000000001811	2021	Coincidental Expression of Classic Hodgkin Lymphoma and Neurofibromatosis Type I and Literature Review.	NF1
32925410	10.1097/MPH.0000000000001936	2021	Further Lessons Learned From a Child With NF1 and Classical Hodgkin Lymphoma.	NF1
32929178	10.1038/s41379-020-00673-x	2021	The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.	NF1
33211573	10.2214/AJR.19.22283	2021	Imaging Features of Neurofibromatosis Type 1 in the Abdomen and Pelvis.	NF1
33395032	10.1097/CCO.0000000000000711	2021	MEK inhibitors in RASopathies.	NF1
33669386	10.3390/ijms22041954	2021	Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.	NF1
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	NF1
34011343	10.1186/s13023-021-01856-8	2021	Lymphoproliferative malignancies in patients with neurofibromatosis 1.	NF1
34944796	10.3390/cancers13246174	2021	RNA Sequencing of Primary Cutaneous and Breast-Implant Associated Anaplastic Large Cell Lymphomas Reveals Infrequent Fusion Transcripts and Upregulation of PI3K/AKT Signaling via Neurotrophin Pathway Genes.	NF1
28413392	10.1159/000456029	2020	T-Cell Lymphoma in a Patient with Neurofibromatosis Type 1 and AIDS.	NF1
28487787	10.1155/2017/5083463	2020	EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in <i>ASXL1</i>, <i>BCOR</i>, <i>CDKN2A</i>, <i>NF1</i>, and <i>TP53</i>.	NF1
30774551	10.4103/wjnm.WJNM_11_18	2020	Can we differentiate malignant peripheral nerve sheath tumor from benign neurofibroma without invasive sampling.	NF1
30946933	10.1016/j.humpath.2019.03.004	2020	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.	NF1
31240424	10.1007/s10689-019-00138-4	2020	Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant.	NF1
31257073	10.1016/j.ccell.2019.05.015	2020	RAC1<sup>P29S</sup> Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.	NF1
31261022	10.1016/j.leukres.2019.106177	2020	High resolution Chromosomal Microarray Analysis (CMA) enhances the genetic profile of pediatric B-cell Acute Lymphoblastic Leukemia patients.	NF1
31693904	10.1016/j.celrep.2019.09.071	2020	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.	NF1
32104235	10.3892/etm.2020.8418	2020	MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1.	NF1
29354122	10.3389/fimmu.2017.01901	2019	Neurofibromin 1 Impairs Natural Killer T-Cell-Dependent Antitumor Immunity against a T-Cell Lymphoma.	NF1
29636358	10.1158/1078-0432.CCR-17-2452	2019	Resistance Mechanisms to Targeted Therapies in <i>ROS1</i><sup>+</sup> and <i>ALK</i><sup>+</sup> Non-small Cell Lung Cancer.	NF1
29846633	10.1210/jc.2017-01845	2019	Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.	NF1
30280491	10.1002/pbc.27496	2019	Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan.	NF1
30322862	10.1158/0008-5472.CAN-18-1867	2019	Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.	NF1
27102345	10.1038/modpathol.2016.79	2018	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.	NF1
28318056	10.1111/pde.13094	2018	Cutaneous and Systemic Findings in Mosaic Neurofibromatosis Type 1.	NF1
29179212	10.1159/000485415	2018	LukS-PV-Regulated MicroRNA-125a-3p Promotes THP-1 Macrophages Differentiation and Apoptosis by Down-Regulating NF1 and Bcl-2.	NF1
29184034	10.1126/scisignal.aam7550	2018	MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.	NF1
27174491	10.1038/leu.2016.83	2017	MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.	NF1
27181063	10.1016/j.exphem.2016.04.011	2017	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.	NF1
27565932	10.1016/j.lungcan.2016.07.002	2017	Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.	NF1
27628603		2017	Primary Effusion Lymphoma-like Lymphoma in a Patient with Neurofibromatosis Type 1.	NF1
27659822	10.1007/s00381-016-3163-6	2017	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.	NF1
27696251	10.1007/s12020-016-1080-9	2017	Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.	NF1
27976555	10.24953/turkjped.2016.02.005	2017	Are the methylenetetrahydrofolate reductase 1298 and 677 gene polymorphisms related to optic glioma and hamartoma risk in neurofibromatosis type 1 patients?	NF1
27997540	10.1371/journal.pmed.1002200	2017	IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.	NF1
28057529	10.1016/j.bbr.2017.01.003	2017	Genetic inhibition of Anaplastic Lymphoma Kinase rescues cognitive impairments in Neurofibromatosis 1 mutant mice.	NF1
28408464	10.1182/blood-2016-12-758979	2017	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.	NF1
28474981	10.3171/2017.2.PEDS16497	2017	Pediatric meningiomas: 65-year experience at a single institution.	NF1
28629962	10.1016/j.bbr.2017.06.024	2017	Pharmacological inhibition of Anaplastic Lymphoma Kinase rescues spatial memory impairments in Neurofibromatosis 1 mutant mice.	NF1
28694326	10.1182/blood-2017-02-768234	2017	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).	NF1
26073032	10.1111/cge.12625	2016	Neurofibromatosis type 1 and malignancy in childhood.	NF1
26432421	10.1002/cam4.551	2016	Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.	NF1
26536237	10.1371/journal.pgen.1005611	2016	Anaplastic Lymphoma Kinase Acts in the Drosophila Mushroom Body to Negatively Regulate Sleep.	NF1
27013922	10.2174/1389202916666151014221954	2016	Genetics of Bladder Malignant Tumors in Childhood.	NF1
24469042	10.1038/onc.2013.587	2015	SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.	NF1
26002977	10.4049/jimmunol.1402639	2015	Cutting Edge: Codeletion of the Ras GTPase-Activating Proteins (RasGAPs) Neurofibromin 1 and p120 RasGAP in T Cells Results in the Development of T Cell Acute Lymphoblastic Leukemia.	NF1
24217072		2014	Oncologic manifestations in children with neurofibromatosis type 1 in Turkey.	NF1
24278035	10.1371/journal.pgen.1003958	2014	Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency.	NF1
24764718	10.3747/co.21.1803	2014	fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies.	NF1
22294052	10.1007/s10072-011-0886-8	2013	Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease).	NF1
23257896	10.1038/bjc.2012.535	2013	Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study.	NF1
23298878	10.1097/MOH.0b013e32835d82fe	2013	Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.	NF1
23508829	10.1002/gcc.22054	2013	Next-generation-sequencing-based risk stratification and identification of new genes involved in structural and sequence variations in near haploid lymphoblastic leukemia.	NF1
23603912	10.1182/blood-2012-11-465138	2013	Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.	NF1
20435627	10.3324/haematol.2009.011114	2012	Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia.	NF1
21949657	10.1371/journal.pgen.1002281	2012	The receptor tyrosine kinase Alk controls neurofibromin functions in Drosophila growth and learning.	NF1
22146869	10.1007/s00256-011-1333-x	2012	Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis.	NF1
22514921		2012	[Radiation associated leukemia and myelodysplastic syndrome].	NF1
22675565	10.1371/journal.pone.0038463	2012	High accuracy mutation detection in leukemia on a selected panel of cancer genes.	NF1
22920205		2012	[Constitutional mismatch repair-deficiency syndrome (CMMR-D) - a case report of a family with biallelic MSH6 mutation].	NF1
20065082	10.3324/haematol.2009.010413	2011	Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults.	NF1
21642990	10.1038/ng.858	2011	A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL).	NF1
20007546	10.1182/blood-2009-04-216184	2010	Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.	NF1
20067559	10.1111/j.1365-2141.2009.08056.x	2010	Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study.	NF1
20428205	10.1038/leu.2010.81	2010	Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib.	NF1
18172006	10.1182/blood-2007-06-095075	2008	Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis.	NF1
17351342	10.4161/cc.6.5.3919	2007	Oncogenes in myeloproliferative disorders.	NF1
17373983	10.1111/j.1468-3083.2006.02013.x	2007	Disseminated xanthogranulomas associated with adult T-cell leukaemia/lymphoma: a case report and review the association of haematologic malignancies.	NF1
17440981	10.1002/cncr.22697	2007	Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies.	NF1
16283678	10.1002/ajmg.a.30998	2006	Neurofibromatosis von Recklinghausen type I phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6.	NF1
16341812	10.1007/s10689-005-8351-6	2006	Syndrome of early onset colon cancers, hematologic malignancies &amp; features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations.	NF1
16818505	10.1158/1535-7163.MCT-06-0012	2006	Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y).	NF1
15561680	10.1182/asheducation-2004.1.118	2005	Childhood and adolescent lymphoid and myeloid leukemia.	NF1
15103715	10.1002/ajmg.a.20651	2004	Non-neurogenic sarcomas in four children and young adults with neurofibromatosis type 1.	NF1
15255115	10.1076/opge.25.1.49.29005	2004	Neurofibromatosis type 1 associated with central nervous system lymphoma.	NF1
12531231	10.1016/s0145-2126(02)00178-9	2003	B lineage acute lymphoblastic leukemia transformation in a child with juvenile myelomonocytic leukemia, type 1 neurofibromatosis and monosomy of chromosome 7. Possible implications in the leukemogenesis.	NF1
12889711		2003	Cutaneous T-cell lymphoma in a patient with neurofibromatosis type 1.	NF1
10979983		2000	Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell.	NF1
10559359	10.1128/JVI.73.12.10406-10415.1999	1999	Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.	NF1
9927033		1999	Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1.	NF1
9796699	10.1038/sj.onc.1202097	1998	NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity.	NF1
8995642	10.1128/JVI.71.2.1196-1206.1997	1997	Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.	NF1
9008333	10.1016/s0378-1135(96)01228-x	1997	Sequence analysis of the putative viral enhancer in tissues from 33 cats with various feline leukemia virus-related diseases.	NF1
9311802	10.1128/JVI.71.10.7273-7280.1997	1997	Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.	NF1
8964492	10.1016/0378-1119(96)00068-6	1996	The role of nuclear factor NF-Y/CP1 in the transcriptional regulation of the human aldehyde dehydrogenase 2-encoding gene.	NF1
7474134	10.1128/JVI.69.11.7138-7146.1995	1995	Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas.	NF1
7564528		1995	Low frequency of RAS gene mutations and absence of mutations within the FLR exon of NF1 in patients with therapy-related leukemias.	NF1
7607657	10.1007/BF00214188	1995	Familial reciprocal translocation t(17;19) (q11.2;q13.2) associated with neurofibromatosis type 1, including one patient with non-Hodgkin lymphoma and an additional t(14;20) in B lymphocytes.	NF1
7718877		1995	Localization of the inducible enhancer in the mouse interleukin-5 gene that is responsive to T-cell receptor stimulation.	NF1
7947106	10.1038/bjc.1994.431	1994	Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study.	NF1
7968792	10.1002/mpo.2950240110	1994	Consecutive glioblastoma and B cell non-Hodgkin's lymphoma in a young child with von Recklinghausen's Neurofibromatosis.	NF1
8126451	10.1099/0022-1317-75-3-545	1994	Cis- and trans-regulation of feline immunodeficiency virus: identification of functional binding sites in the long terminal repeat.	NF1
8177146	10.1002/mpo.2950230110	1994	Juvenile xanthogranuloma and acute leukemia: a case report.	NF1
8259105	10.1002/mpo.2950220203	1994	Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution.	NF1
8388972		1993	Sequential development of Wilms tumor, T-cell acute lymphoblastic leukemia, medulloblastoma and myeloid leukemia in a child with type 1 neurofibromatosis: a clinical and cytogenetic case report.	NF1
1656080	10.1128/JVI.65.11.5933-5943.1991	1991	The enhancer of human papillomavirus type 16: binding sites for the ubiquitous transcription factors oct-1, NFA, TEF-2, NF1, and AP-1 participate in epithelial cell-specific transcription.	NF1
1945411		1991	Regulatory domains within the P0 promoter of human c-myc.	NF1
2042396	10.1016/0168-1702(91)90013-l	1991	A new leukemogenic retrovirus isolated from tumor cells derived from a radio-induced lymphoma of C57BL/6 mice: analysis of the env and LTR sequences.	NF1
2346587	10.1002/mc.2940030207	1990	A single mutation in one of the CORE elements of Moloney murine leukemia virus reduced binding of a 42-kDa T lymphoma cell nuclear factor but did not affect lymphomagenesis.	NF1
2783465	10.1128/JVI.63.2.471-480.1989	1989	The reduced virulence of the thymotropic Moloney murine leukemia virus derivative MoMuLV-TB is mapped to 11 mutations within the U3 region of the long terminal repeat.	NF1
